Effect of remote ischemic conditioning on pain-free walking distance and angiogenesis in patients with chronic arterial occlusive disease.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025735

Enrollment

200

Registered

2021-07-01

Start date

2024-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70.29

Interventions

Group 1: Study group 1: Remote ischemic conditioning (3 x 5min ischemia + 5 min reperfusion) for 4 weeks + Best Medical Treatment. Group 2: Study group 2 (control group): best medical treatment (BMT)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: - paVk stage IIb; - written informed consent

Exclusion criteria

Exclusion criteria: - Age 75 years - Current participation in another clinical intervention study - Participation in another clinical intervention study within the last 30 days -Cognitive/language barriers, comprehension problems during the educational process - Severe renal and hepatic insufficiency - Severe COPD (FeV1= 50%). - Existing drug and alcohol abuse - Neurological diseases (Parkinson's disease, multiple sclerosis, epilepsy, Alzheimer's disease) - Acute infections - Diabetes mellitus - Pronounced pAVK of the upper extremities - Polyneuropathy of the upper extremities - Arterio-venous fistula (shunt) or lymphedema of the upper extremities - Myocardial infarction 3 missed RIC applications.

Design outcomes

Primary

Measure	Time frame
Pain-free and total walking distance determined using the standardized treadmill test	—

Secondary

Measure	Time frame
(1)Does RIC lead to improved microcirculation of the affected extremities (measured by thermal imaging camera)? (2)Does RIC lead to an improvement in quality of life (SF-36 quality of life questionnaire)? (3)What is the impact of RIC on renal function? (4)Does long-term RIC change the activity of atherosclerotic inflammatory response (Il-1,Il-6, hs-CRP, fibrinogen)? (5)Do molecular and protein biochemical changes in serum and tissue samples occur as a result of RIC? (6)Does RIC increase the number of endothelial progenitor cells in the blood. Translated with www.DeepL.com/Translator (free version)	—

Measure

Time frame

(1)Does RIC lead to improved microcirculation of the affected extremities (measured by thermal imaging camera)? (2)Does RIC lead to an improvement in quality of life (SF-36 quality of life questionnaire)? (3)What is the impact of RIC on renal function? (4)Does long-term RIC change the activity of atherosclerotic inflammatory response (Il-1,Il-6, hs-CRP, fibrinogen)? (5)Do molecular and protein biochemical changes in serum and tissue samples occur as a result of RIC? (6)Does RIC increase the number of endothelial progenitor cells in the blood. Translated with www.DeepL.com/Translator (free version)

—

Countries

Germany

Contacts

Public ContactRené Rusch

Klinik für Herz- und Gefäßchirurgie

rene.rusch@uksh.de+4943150022032

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 14, 2026